The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Docon Technologies Pvt Ltd
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Docon Technologies Pvt Ltd, a promoter and holding company of Thyrocare, sold 53,32,860 equity shares (about 10.05% of paid-up capital) on October 24, 2025 through open-market trades. Promoter holding fell from 70.98% to 60.93%, but Docon continues to be classified as a Promoter & Holding Company. An interesting detail: before the sale, 60.93% of Docon's stake (3,23,23,232 shares) was shown as encumbered/pledged; after the sale, encumbrance dropped to zero, indicating a large release of pledged shares. Docon is itself a wholly owned subsidiary of API Holdings Ltd.
A 10% promoter stake sale of this size is large enough to pressure the stock in the short term, but control remains comfortable at ~61% and the promoter tag is intact. The full release of pledged shares is a positive sign, removing a major overhang and leverage risk for the promoter group.